Other
Other Comprehensive Income (Loss)
Year-over-year, this metric declined by 847.1%, from $1.70M to -$12.70M. Over 3 years (FY 2021 to FY 2025), Other Comprehensive Income (Loss) shows an upward trend with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
A large positive value suggests favorable currency or market movements, while a large negative value indicates potential future volatility in equity.
Detailed definition
This represents the aggregate of all items of other comprehensive income or loss, which are excluded from net income und...
Peer comparison
Standardized across all public companies under GAAP/IFRS reporting requirements.
Metric ID:
tmusz_other_comprehensive_income_lossHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$300.00K | -$300.00K | -$2.10M | -$7.60M | -$2.90M | -$1.80M | $4.00M | $700.00K | $800.00K | $7.00M | -$3.20M | -$900.00K | $9.10M | -$5.10M | $1.70M | $2.70M | -$900.00K | $0.00 | -$12.70M |
| QoQ Change | — | +0.0% | -600.0% | -261.9% | +61.8% | +37.9% | +322.2% | -82.5% | +14.3% | +775.0% | -145.7% | +71.9% | >999% | -156.0% | +133.3% | +58.8% | -133.3% | +100.0% | — |
| YoY Change | — | — | — | — | -866.7% | -500.0% | +152.6% | +124.1% | +144.4% | — | -180.0% | -228.6% | >999% | -172.9% | +153.1% | +400.0% | -109.9% | +100.0% | -847.1% |
Range-$12.70M – $9.10M
CAGR+129.9%
Avg YoY Growth-56.7%
Median YoY Growth-4.9%
Other Comprehensive Income (Loss) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's other comprehensive income (loss)?
- Neurocrine Biosciences (NBIX) reported other comprehensive income (loss) of -$12.70M in Q1 2026.
- How has Neurocrine Biosciences's other comprehensive income (loss) changed year-over-year?
- Neurocrine Biosciences's other comprehensive income (loss) decreased by 847.1% year-over-year, from $1.70M to -$12.70M.
- What is the long-term trend for Neurocrine Biosciences's other comprehensive income (loss)?
- Over 3 years (2021 to 2025), Neurocrine Biosciences's other comprehensive income (loss) has grown at a 0.0% compound annual growth rate (CAGR), from -$3.50M to $3.50M.
- What does other comprehensive income (loss) mean?
- The total of all gains and losses that are recorded directly in equity rather than through the income statement.